This content is in French.
TIGIT: Brake or Springboard Against Cancer?
5 février 2025
#Oncology #Immunotherapy #TIGIT #Cancer #TherapeuticCombination #NKCell #TLymphocyte #PredictiveBiomarker
Immunotherapy has revolutionized cancer treatment by leveraging the immune system to fight tumor cells. However, despite its successes, it often faces resistance that limits its effectiveness, particularly in advanced cancers. Among the mechanisms of tumor immune evasion, the role of TIGIT (T-cell immunoreceptor with Ig and ITIM domains) has garnered increasing attention.
Immunotherapy has revolutionized cancer treatment by leveraging the immune system to fight tumor cells. However, despite its successes, it often faces resistance that limits its effectiveness, particularly in advanced cancers. Among the mechanisms of tumor immune evasion, the role of TIGIT (T-cell immunoreceptor with Ig and ITIM domains) has garnered increasing attention.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Zhang, P., et al. (2024). Targeting TIGIT for cancer immunotherapy: recent advances and future directions. Biomarker Research, 12(1), 7
View the source
